First AD

Second AD

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02 

Please discuss the significance of TROP2 in the development and progression of NSCLC and the role of TROP2-directed ADCs in this treatment setting.

         a. How is TROP2 unique as a biomarker in NSCLC?

         b. In what ways does it differ from other targetable biomarkers in NSCLC?

         c. What is the rationale for TROP2-directed therapies in previously treated        

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates  

Peer Exchange

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC